Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results.

(2022) Nick Pavlakis et al.   JOURNAL OF CLINICAL ONCOLOGY

887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial

(2022) E. Baudin et al.   ANNALS OF ONCOLOGY

Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

(2021) Valentina Ambrosini et al.   EUROPEAN JOURNAL OF CANCER

External validity of somatostatin analogues trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study

(2021) Paula Jimenez-Fonseca et al.   NEUROENDOCRINOLOGY

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

(2021) Baptiste Camus et al.   Journal of Clinical Medicine

Efficacy and safety of 177Lu-DOTATATE in lung neuroendocrine tumors: a bi-center study

(2021) Lamiaa Zidan et al.   JOURNAL OF NUCLEAR MEDICINE

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

(2021) Jonathan R Strosberg et al.   LANCET ONCOLOGY

Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs)

(2020) Eitan Mirvis et al.   LUNG CANCER

A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation

(2019) Kolasinska-Ćwikła et al.   Journal of Clinical Medicine

Peptide Receptor Radionuclide Therapy in the Management of Advanced Pheochromocytoma and Paraganglioma: A Systematic Review and Meta‐analysis

(2019) Swayamjeet Satapathy et al.   CLINICAL ENDOCRINOLOGY

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

(2019) Alberto Carmona-Bayonas et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

(2018) Ulrike Garske-Román et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

(2018) Guido Rindi et al.   MODERN PATHOLOGY

1335TiPCOMPETE trial: Peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide vs. everolimus in progressive GEP-NET

(2018) M E Pavel et al.   ANNALS OF ONCOLOGY

Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas

(2017) Konstantinos Nastos et al.   JOURNAL OF SURGICAL ONCOLOGY

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors

(2017) Alberto Carmona-Bayonas et al.   Current Oncology Reports

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

(2017) Bryan Oronsky et al.   NEOPLASIA

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up

(2016) Dieter Hörsch et al.   EUROPEAN JOURNAL OF CANCER

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

(2016) B. Niederle et al.   NEUROENDOCRINOLOGY

Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development

(2015) Rocio Garcia-Carbonero et al.   CANCER AND METASTASIS REVIEWS

Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET

(2015) Annarita Ianniello et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Long-term results of PRRT in advanced bronchopulmonary carcinoid

(2015) Annapaola Mariniello et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Tuning multiple imputation by predictive mean matching and local residual draws

(2014) Tim P Morris et al.   BMC Medical Research Methodology

Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours

(2014) Samer Ezziddin et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients

(2013) D. Westreich et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

(2011) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors

(2011) Jens Hasskarl et al.   Future Oncology

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

(2011) Anna Imhof et al.   JOURNAL OF CLINICAL ONCOLOGY

NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor

(2010) Aaron I. Vinik et al.   PANCREAS

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE